摘要
发生小细胞肺癌(small cell lung cancer, SCLC)组织学转化是非小细胞肺癌(non-small cell lung cancer, NSCLC)使用酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)治疗过程中并不常见但十分重要的耐药机制。发生转化后的患者一般预后较差,其发生机制和应对疗法是目前临床研究的难题。而TP53/RB1通路的改变被认为是发生转化的重要条件。本文对近年来TP53/RB1在转化中的研究现状做一综述。
Histological transformation of small cell lung cancer(SCLC)is an uncommon but important drug resistance mechanism in the treatment of non-small cell lung cancer(NSCLC)with tyrosine kinase inhibitor(TKI).The prognosis of patients with transformation is generally poor,and its pathogenesis and coping therapy are difficult problems in clinical research at present.The change of TP53/RB1 pathway is considered as an important condition for transformation.In this paper,the research status of TP53/RB1 in transformation in recent years is reviewed.
作者
安婧
马晓梅
An Jing;Ma Xiaomei(Cancer Hospital Affiliated to Xinjiang Medical University,Wulumuqi Xinjiang 830054,China)
出处
《生命科学仪器》
2025年第1期116-117,120,共3页
Life Science Instruments
